{
  "ticker": "LLY",
  "target_date": "2025-07-09",
  "actual_date": "2025-07-09",
  "collected_at": "2025-12-08T11:59:34.808392",
  "price": {
    "open": 780.94,
    "high": 791.1,
    "low": 779.13,
    "close": 784.0439453125,
    "volume": 2703100,
    "change_1d_pct": 1.19,
    "change_7d_pct": 1.48,
    "change_30d_pct": 10.26
  },
  "technicals": {
    "rsi_14": 48.12,
    "sma_20": 785.03,
    "sma_50": 771.48,
    "macd": 2.795,
    "macd_signal": 4.072,
    "macd_histogram": -1.277,
    "bb_upper": 816.39,
    "bb_lower": 753.67,
    "price_vs_sma20_pct": -0.13,
    "price_vs_sma50_pct": 1.63,
    "volume_ratio": 0.87
  },
  "fundamentals": {
    "market_cap": 893740449792,
    "pe_ratio": 48.847134,
    "forward_pe": 43.99691,
    "price_to_book": 37.536522,
    "price_to_sales": 15.0411215,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.34,
    "pct_from_52w_low": 59.83
  },
  "macro": {
    "spy": {
      "price": 622.33,
      "change_1d_pct": 0.6,
      "change_7d_pct": 1.01
    },
    "vix": {
      "level": 15.94,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.34
    },
    "dollar_index": {
      "level": 97.47
    },
    "gold": {
      "price": 3311.6
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly",
      "source": "Yahoo",
      "datetime": 1752099360,
      "summary": "Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year.  Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to be a dominant player in the weight loss and diabetes markets.  Eli Lilly (NYSE: LLY) and Novo Nordisk ",
      "url": "https://finnhub.io/api/news?id=01bba6fb2e39c86c6c5303c70c340d3cd7ff350a779969f83a2d920a29f8e8ed"
    },
    {
      "headline": "Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know",
      "source": "Yahoo",
      "datetime": 1752097503,
      "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $786.92, indicating a +1.19% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=defcd7e7490655ae8c9fd05d04883ec4dba7afd38a70b56392269ec9b934b77a"
    },
    {
      "headline": "Eli Lilly (NYSE:LLY) Gains FDA Approval For New Alzheimer's Drug Dosing Schedule",
      "source": "Yahoo",
      "datetime": 1752082533,
      "summary": "Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related imaging abnormalities in Alzheimer's treatment. This development comes amid a 3% price increase for the company in the last quarter. Despite these gains, market activity remain",
      "url": "https://finnhub.io/api/news?id=41ab4da7513a60aee07c802b952362083243db019e5f964b1df1b4af4bb1a17d"
    },
    {
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "source": "MarketWatch",
      "datetime": 1752078660,
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=a1c6d282e5fbf64c671be6b81afc437661ca6cfd82374b96559b2a16dbc75b49"
    },
    {
      "headline": "Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?",
      "source": "Yahoo",
      "datetime": 1752076080,
      "summary": "NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.",
      "url": "https://finnhub.io/api/news?id=eb7a3324c98ee8e8e5436f5f101d805a510c9194fc419581f4279ec1906e510a"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199300.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000176/xslF345X05/wk-form4_1750199300.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199159.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000174/xslF345X05/wk-form4_1750199159.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198988.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000172/xslF345X05/wk-form4_1750198988.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198711.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000170/xslF345X05/wk-form4_1750198711.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198504.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000168/xslF345X05/wk-form4_1750198504.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}